ADIE-BC - Aligning Dimensions of Interoceptive Experience in Breast Cancer Survivors

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A breast cancer diagnosis can lead to significant anxiety, and for many survivors, this anxiety continues well beyond the end of treatment. While standard anxiety therapies are helpful for some, these therapies often fall short for breast cancer survivors due to an individual's unique experience-particularly changes in how survivors perceive and relate to the body, a process known as interoception. The study will evaluate the feasibility and acceptability of a novel interoceptive training approach called ADIE Therapy. ADIE Therapy trains participants to better recognise bodily signals, and has shown promising results in reducing anxiety in non-cancer populations. The aim of the study is to assess the acceptability and feasibility of ADIE Therapy for breast cancer survivors.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years old or older

• Residing in the UK and able to travel into London

• Can read and write in English

• Have had a diagnosis of Primary Breast Cancer

• Have completed active, hospital-based treatment for primary breast cancer (Stages 1, 2 or 3; this refers to radiotherapy, surgery, or chemotherapy) 6 months - 10 years previously (this does not apply to ongoing endocrine (hormone) therapy)

Locations
Other Locations
United Kingdom
King's College London
RECRUITING
London
Contact Information
Primary
Lauren C. Heathcote, PhD
lauren.heathcote@kcl.ac.uk
2071882597
Backup
Georgina Lockwood-Taylor, PhD Candidate
georgina.lockwood-taylor@kcl.ac.uk
Time Frame
Start Date: 2025-05
Estimated Completion Date: 2025-10
Participants
Target number of participants: 15
Treatments
Experimental: ADIE Therapy
Participants will undergo 6 sessions of cardiac interoceptive training (ADIE Therapy).
Related Therapeutic Areas
Sponsors
Collaborators: Brighton & Sussex Medical School, University College, London
Leads: King's College London

This content was sourced from clinicaltrials.gov